5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders: The iceberg still lies beneath the surface

Fakhfouri, G. and Rahimian, R. and Dyhrfjeld-Johnsen, J. and Zirak, M. R. and Beaulieu, J. M. (2019) 5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders: The iceberg still lies beneath the surface. Pharmacological Reviews, 71 (3). pp. 383-412.

[img] Text
5-HT3 receptor antagonists in neurologic and neuropsychiatric disorders The iceberg still lies beneath the surface.pdf

Download (930kB)

Abstract

5-HT3 receptor antagonists, first introduced to the market in the mid-1980s, are proven efficient agents to counteract chemotherapy-induced emesis. Nonetheless, recent investigations have shed light on unappreciated dimensions of this class of compounds in conditions with an immunoinflammatory component as well as in neurologic and psychiatric disorders. The promising findings from multiple studies have unveiled several beneficial effects of these compounds in multiple sclerosis, stroke, Alzheimer disease, and Parkinson disease. Reports continue to uncover important roles for 5-HT3 receptors in the physiopathol-ogy of neuropsychiatric disorders, including depression, anxiety, drug abuse, and schizophrenia. This review addresses the potential of 5-HT3 receptor antagonists in neurology-and neuropsychiatry-related disorders. The broad therapeutic window and high compliance observed with these agents position them as suitable prototypes for the development of novel pharmacother-apeutics with higher efficacy and fewer adverse effects. © 2019 by The Author(s).

Item Type: Article
Additional Information: Cited By :1 Export Date: 16 February 2020 CODEN: PAREA Correspondence Address: Beaulieu, J.-M.; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Medical Science BuildingCanada; email: martin.beaulieu@utoronto.ca
Uncontrolled Keywords: antineoplastic agent ligand serotonin 3 agonist serotonin 3 antagonist serotonin 3 receptor allosterism anticonvulsant activity antidepressant activity anxiety disorder Article cancer chemotherapy cerebrovascular accident cholinergic system competitive inhibition depression diabetes mellitus drug abuse drug effect drug mechanism drug therapeutic index genetic screening glucose blood level glucose intolerance human inner ear disease insulin release irritable colon memory disorder mental disease microglia neurologic disease neurology neuromodulation neuropathology neuropsychiatry neurotoxicity neurotransmission nonhuman obsessive compulsive disorder parkinsonism posttraumatic stress disorder priority journal protein localization protein structure risk factor schizophrenia seizure side effect tranquilizing activity animal metabolism Animals Humans Mental Disorders Nervous System Diseases Receptors, Serotonin, 5-HT3 Serotonin 5-HT3 Receptor Antagonists
Subjects: QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 21 Jun 2020 05:11
Last Modified: 21 Jun 2020 05:11
URI: http://eprints.mums.ac.ir/id/eprint/18323

Actions (login required)

View Item View Item